ICARES Medicus, Inc. (TPEX:6612)
Taiwan · Delayed Price · Currency is TWD 73.30
-0.10 (-0.14%)
Aug 19, 2026, 1:30 PM CST
ICARES Medicus Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,210 | 1,131 | 859.79 | 605.45 | 511.85 | 393.92 | |
Revenue Growth | 12.00% | 31.54% | 42.01% | 18.29% | 29.94% | 8.62% |
Cost of Revenue | 527.03 | 462.81 | 260.06 | 123.05 | 94.41 | 71.04 |
Gross Profit | 683.39 | 668.18 | 599.73 | 482.4 | 417.44 | 322.89 |
Selling, General & Admin | 410.2 | 380.82 | 277.97 | 186.31 | 157.23 | 127 |
Research & Development | 157.96 | 158.94 | 192.7 | 177.45 | 133.08 | 104.87 |
Operating Expenses | 565.37 | 539.6 | 476.48 | 373.84 | 292.73 | 235.03 |
Operating Income | 118.01 | 128.58 | 123.25 | 108.56 | 124.71 | 87.85 |
Interest Expense | -22.25 | -24.19 | -18.33 | -7.17 | -0.58 | -0.83 |
Interest & Investment Income | 19.95 | 18.74 | 44.45 | 5.29 | 2.67 | 2.48 |
Earnings From Equity Investments | 1.62 | 3.66 | 2.38 | -1.35 | -4.18 | -2.17 |
Currency Exchange Gain (Loss) | -18.67 | -18.67 | 8.64 | 0.93 | 15.72 | -4.81 |
Other Non Operating Income (Expenses) | 67.84 | 13.38 | 3.44 | 4.56 | 5.1 | 3.99 |
EBT Excluding Unusual Items | 166.5 | 121.51 | 163.84 | 110.82 | 143.44 | 86.51 |
Gain (Loss) on Sale of Investments | -9.35 | -9.35 | 0.57 | 2.47 | -0.33 | -13.32 |
Other Unusual Items | -44.43 | -44.43 | - | - | - | - |
Pretax Income | 112.72 | 67.73 | 164.4 | 113.29 | 143.11 | 73.19 |
Income Tax Expense | 82.21 | 64.66 | 109.89 | 48.86 | 32.72 | 35.82 |
Earnings From Continuing Operations | 30.51 | 3.07 | 54.51 | 64.43 | 110.39 | 37.37 |
Minority Interest in Earnings | 63.05 | 48.16 | 48.61 | 33.3 | 18.52 | 21.23 |
Net Income | 93.56 | 51.23 | 103.12 | 97.73 | 128.91 | 58.6 |
Net Income to Common | 93.56 | 51.23 | 103.12 | 97.73 | 128.91 | 58.6 |
Net Income Growth | -0.75% | -50.32% | 5.52% | -24.19% | 119.97% | 12.90% |
Shares Outstanding (Basic) | 47 | 47 | 47 | 42 | 41 | 41 |
Shares Outstanding (Diluted) | 47 | 47 | 47 | 42 | 41 | 41 |
Shares Change | 0.95% | 0.03% | 11.53% | 2.91% | 0.74% | 0.38% |
EPS (Basic) | 1.97 | 1.09 | 2.19 | 2.32 | 3.15 | 1.44 |
EPS (Diluted) | 1.97 | 1.08 | 2.18 | 2.31 | 3.13 | 1.44 |
EPS Growth | -1.80% | -50.46% | -5.59% | -26.28% | 117.82% | 12.99% |
Free Cash Flow | -81.72 | -108.35 | -197.49 | -96.74 | 97.47 | 33.18 |
Free Cash Flow Per Share | -1.72 | -2.29 | -4.18 | -2.28 | 2.37 | 0.81 |
Dividend Per Share | 0.300 | 0.300 | 0.300 | 0.165 | 0.826 | 0.413 |
Dividend Growth | 0% | 0% | 81.49% | -80.00% | 100.00% | 400.24% |
Gross Margin | 56.46% | 59.08% | 69.75% | 79.68% | 81.56% | 81.97% |
Operating Margin | 9.75% | 11.37% | 14.34% | 17.93% | 24.37% | 22.30% |
Profit Margin | 7.73% | 4.53% | 11.99% | 16.14% | 25.19% | 14.88% |
Free Cash Flow Margin | -6.75% | -9.58% | -22.97% | -15.98% | 19.04% | 8.42% |
EBITDA | 236.15 | 235.44 | 180.13 | 129.33 | 142.69 | 106.87 |
EBITDA Margin | 19.51% | 20.82% | 20.95% | 21.36% | 27.88% | 27.13% |
D&A For EBITDA | 118.13 | 106.86 | 56.87 | 20.77 | 17.97 | 19.02 |
EBIT | 118.01 | 128.58 | 123.25 | 108.56 | 124.71 | 87.85 |
EBIT Margin | 9.75% | 11.37% | 14.34% | 17.93% | 24.37% | 22.30% |
Effective Tax Rate | 72.93% | 95.47% | 66.84% | 43.13% | 22.86% | 48.94% |